MONTREAL & MALVERN, Pa.--(BUSINESS WIRE)--Gemin X announced today the initiation of a Phase 1/2 clinical trial of GX15-070 in combination with docetaxel (Taxotere®), a chemotherapeutic agent, in patients with non-small cell lung cancer (NSCLC), and a Phase 1 trial in combination with bortezomib (Velcade®), a proteosome inhibitor, in patients with mantle cell lymphoma (MCL). GX15-070 is a small molecule specifically designed to inhibit all relevant members of the Bcl-2 protein family, a validated cancer target, thus restoring the natural cell death process of apoptosis.
